Swiss - Delayed Quote CHF

Galderma Group N (GALD.SW)

100.30
+0.55
+(0.55%)
At close: May 12 at 5:30:25 PM GMT+2
Loading Chart for GALD.SW
  • Previous Close 99.75
  • Open 99.00
  • Bid --
  • Ask --
  • Day's Range 97.60 - 101.30
  • 52 Week Range 64.75 - 119.60
  • Volume 347,702
  • Avg. Volume 749,464
  • Market Cap (intraday) 23.812B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 125.38
  • EPS (TTM) 0.80
  • Earnings Date Jul 24, 2025
  • Forward Dividend & Yield 0.15 (0.15%)
  • Ex-Dividend Date Apr 25, 2025
  • 1y Target Est 110.26

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.

www.galderma.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GALD.SW

View More

Performance Overview: GALD.SW

Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

GALD.SW
0.17%
MSCI WORLD (^990100-USD-STRD)
2.13%

1-Year Return

GALD.SW
43.22%
MSCI WORLD (^990100-USD-STRD)
11.06%

3-Year Return

GALD.SW
89.25%
MSCI WORLD (^990100-USD-STRD)
43.18%

5-Year Return

GALD.SW
89.25%
MSCI WORLD (^990100-USD-STRD)
84.31%

Compare To: GALD.SW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GALD.SW

View More

Valuation Measures

As of 5/12/2025
  • Market Cap

    23.81B

  • Enterprise Value

    25.73B

  • Trailing P/E

    124.21

  • Forward P/E

    44.84

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.45

  • Price/Book (mrq)

    3.67

  • Enterprise Value/Revenue

    6.96

  • Enterprise Value/EBITDA

    32.23

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.20%

  • Return on Assets (ttm)

    3.34%

  • Return on Equity (ttm)

    3.51%

  • Revenue (ttm)

    4.44B

  • Net Income Avi to Common (ttm)

    231M

  • Diluted EPS (ttm)

    0.80

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    457M

  • Total Debt/Equity (mrq)

    35.42%

  • Levered Free Cash Flow (ttm)

    131.38M

Research Analysis: GALD.SW

View More

People Also Watch